Novo Nordisk A/S (NYSE:NVO) Stock Sees Unusually High Call Option Buying

Novo Nordisk A/S (NYSE:NVO) was the target of unusually large options trading on Wednesday. Traders purchased 63,116 call options on the stock. This represents an increase of 14% compared to the typical daily volume of 55,182 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NVO shares. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Jefferies Financial Group restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $59.44.

Novo Nordisk A/S Trading Up 6.4%

Shares of NVO stock traded up $2.58 on Wednesday, hitting $42.77. The stock had a trading volume of 13,690,729 shares, compared to its average volume of 16,399,420. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a fifty day moving average price of $40.97 and a two-hundred day moving average price of $44.15. The firm has a market cap of $190.96 billion, a P/E ratio of 10.43, a PEG ratio of 1.37 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.73 by $0.15. The business had revenue of $12 billion for the quarter, compared to the consensus estimate of $11.07 billion. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat Q3 earnings and revenue estimates, reporting $0.88 per share versus $0.73 expected and $12 billion in revenue versus $11.07 billion expected. Obesity-drug sales rose 22%, supporting the results. Article: NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 sales and operating-profit outlook. Stronger obesity-treatment demand, including outside the U.S., and Wegovy pill sales that reportedly exceeded expectations helped drive the upgrade. Article: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: CEO Mike Doustdar said patient volumes have grown strongly despite pricing-related pressure, and played down the prospect of dramatic changes to the company’s business environment. These comments may ease investor concerns about pricing and policy risks. Article: Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears
• Neutral Sentiment: Novo disclosed that CFO Karsten Munk Knudsen will leave the company. The announcement adds a leadership transition to the news flow, but no further details on its impact were provided. Article: Novo Nordisk’s CFO Karsten Munk Knudsen to leave company
• Negative Sentiment: Diabetes weakness and pricing pressures remain risks to growth. Impairment charges also weighed on reported operating profit, although adjusted results were stronger than expected. Article: Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%

Institutional Trading of Novo Nordisk A/S

Large investors have recently bought and sold shares of the business. CoreCap Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock valued at $256,000 after purchasing an additional 242 shares in the last quarter. Claro Advisors Inc. raised its holdings in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Claro Advisors Inc. now owns 21,868 shares of the company’s stock worth $829,000 after buying an additional 256 shares in the last quarter. Carson Advisory Inc. raised its holdings in shares of Novo Nordisk A/S by 2.2% during the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock worth $453,000 after buying an additional 268 shares in the last quarter. Byrne Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company’s stock worth $114,000 after buying an additional 270 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT grew its position in Novo Nordisk A/S by 0.6% in the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after acquiring an additional 272 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.